HPV in Blood Samples From Cervical Cancer Patients.

HPV-Related Carcinoma Clinical Trial

Official title:

Can Digital Droplet PCR (ddPCR) on Blood Samples From Patients With HPV Related Cancers Become a Reality in Cancer Treatment and Monitoring?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03749720
• Other study ID #: U416
• Status: Completed
• Phase: N/A
• Start date: June 15, 2018
• Est. completion date: October 30, 2022

Study information

• Verified date: September 2021
• Source: University of Aarhus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

By means of digital droplet PCR (ddPCR), this study examines blood samples from patients newly diagnosed with cervical cancer to investigate whether it is possible to measure the presence and amount of HPV DNA in these blood samples. The first blood sample is taken at time of diagnosis, and follow-up blood samples are collected during treatment- and follow-up visits. We expect to find a correlation between the disease stage and the viral load and also a decline in viral load after treatment. Furthermore, we hope that this method may serve as a way of detecting disease recurrence earlier than what is possible today.

Description:

This study hypothesises that in patients with HPV-related cervical cancer, HPV DNA may be released into the bloodstream from tumor cells. These fragments of HPV DNA shed by tumor may therefore be measured in blood samples from the patients. By using the same setting as for real-time PCR with PCR primers and probes for fluorescence detection, the study uses digital droplet PCR (ddPCR), a method based on dilution and partitioning of the blood sample in many reaction chambers or droplets, to measure absolute quantities of HPV DNA fragments in blood samples from women with different stages of cervical cancer. Patients are recruited at the time of diagnosis, where a baseline blood sample is collected. Follow-up blood samples are collected during treatment and at follow-up visits up to two years after the diagnosis. We expect the HPV DNA load to decrease after treatment, and if an increase in viral load is detected during follow-up, we expect this to be an early sign of a disease recurrence. The method may therefore become an effective monitoring tool in these patients in terms of detecting a ongoing disease recurrence, which gives us the chance to intervene and treat these patients before the disease becomes too disseminated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 141
• Est. completion date: October 30, 2022
• Est. primary completion date: October 30, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria cases:

• Diagnosed with cervical cancer = stage 1B between june 2018 and june 2020

• > 18 years of age at the time of diagnosis

• There must be available cervical tissue material from the patient to analyse for HPV

Inclusion Criteria healthy controls

• Women > 18 years with no prior history of any cervical dysplasia

Inclusion Criteria CIN3 controls

• Women > 18 years

• Must have a histologically verified severe cervical dysplasia (CIN3)

• Is admitted for cervical conisation

Exclusion Criteria cases:

• < 18 years of age at time of cervical cancer diagnosis

• Cervical cancer < stage 1B

Exclusion Criteria healthy controls:

• < 18 years of age

• Prior cervical dysplasia

Exclusion Criteria CIN3 controls:

• < 18 years of age

• Women with only low grades of cervical dysplasia (CIN1 or CIN2)

• Women with HPV-negative cervical biopsies

Related Conditions & MeSH terms

• HPV-Related Carcinoma
• HPV-Related Malignancy
• Neoplasms

Intervention

Other:
• Blood sample
Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.

Locations

Country	Name	City	State
Denmark	Department of Obstetrics and Gynecology	Aarhus
Denmark	Department of Obstetrics and Gynecolgy	Odense

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HPV DNA	A qualitative and quantitative measure of HPV DNA in blood samples.	Two years